Transformational cell therapies for patients with pancreatic disease

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

Matthew Lehman,

Chief Executive Officer (Koligo Therapeutics Inc.) and Executive Director

  • Proven biotech & cell therapy executive
  • NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
  • Clinical research & manufacturing scale-up expertise
  • MS Columbia; BA Louisville

Stuart Williams, PhD,

Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director

  • Division chief, Bioficial Heart, Cardiovascular Innovation Institude
  • 300+ publications & 16 issued US patents in cell & tissue engineering
  • Experienced academic-industry partner: founded three biotech companies
  • PhD cell biology University of Delaware, postdoc Yale School of Medicine

Peter James,

Non-Executive Director

  • 30+ years’ experience in emerging technologies
  • Extensive experience as Chair, Non-Executive Director and CEO of both publicly listed and private companies

Jethro Marks,

Non-Executive Director

  • Co-founder and CEO of The Nile and Mercury Retail, a leading Australian eCommerce service provider
  • 15+ years’ experience in marketing

Robert Clisdell,

Non-Executive Director

  • Head of Bergen Capital LLC Australian office
  • Extensive experience as director for publicly traded corporations
  • 15+ years’ experience in banking, finance and accounting as an investment banker with Credit Suisse and Caliburn Partnership
  • Graduate Diploma in Applied Finance and Investment from FINSIA

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.